A recent study published in the American Journal of Cardiology found that patients with non-obstructive hypertrophic cardiomyopathy and diabetes showed significant improvements to diastolic heart function and BNP (a hormone produced by the body which indicates heart wall stress) from the use of a drug used for diabetes known as a sodium glucose co-transponder 2 inhibitor (SGLT2).
This class of drugs is commonly used to lower blood sugar in diabetics. One SGLT2 in common usage is Jardiance (empagliflozin).
Since treatments for non-obstructive HCM patients are so limited, this class of drugs presents a potential treatment opportunity for non-diabetic HCM patients as well.
Hey all you researchers out there – sounds like a good clinical trial!
HCM Beat 